S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
Record Store Day celebrates indie retail music sellers as they ride vinyl's popularity wave
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
Record Store Day celebrates indie retail music sellers as they ride vinyl's popularity wave
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
Record Store Day celebrates indie retail music sellers as they ride vinyl's popularity wave
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
Record Store Day celebrates indie retail music sellers as they ride vinyl's popularity wave

Regeneron Pharmaceuticals (REGN) Earnings Date, Estimates & Call Transcripts

$896.82
+2.83 (+0.32%)
(As of 04/19/2024 ET)

Earnings Summary

Upcoming
Earnings Date
May. 2
Before Market Opens
Confirmed
Actual EPS
(Feb. 2)
$11.86 Beat By $1.13
Consensus EPS
(Feb. 2)
$10.73
Skip Charts & View Estimated and Actual Earnings Data

REGN Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

REGN Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Regeneron Pharmaceuticals Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20242$7.48$8.05$7.77
Q2 20242$9.59$9.67$9.63
Q3 20242$9.80$11.42$10.61
Q4 20242$7.72$10.57$9.15
FY 20248$34.59$39.71$37.15

REGN Earnings Date and Information

Regeneron Pharmaceuticals last issued its quarterly earnings data on February 2nd, 2024. The biopharmaceutical company reported $11.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $10.73 by $1.13. The business had revenue of $3.43 billion for the quarter, compared to analysts' expectations of $3.29 billion. Its quarterly revenue was up .6% on a year-over-year basis. Regeneron Pharmaceuticals has generated $34.75 earnings per share over the last year ($34.75 diluted earnings per share) and currently has a price-to-earnings ratio of 25.8. Earnings for Regeneron Pharmaceuticals are expected to grow by 3.99% in the coming year, from $38.59 to $40.13 per share. Regeneron Pharmaceuticals has confirmed that its next quarterly earnings report will be published on Thursday, May 2nd, 2024. Regeneron Pharmaceuticals will be holding an earnings conference call on Thursday, May 2nd at 8:30 AM Eastern. Interested parties can register for or listen to the call..

Regeneron Pharmaceuticals Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
5/2/2024
Confirmed)
-------  
2/2/2024Q4 2023$10.73$11.86+$1.13$10.17$3.29 billion$3.43 billion    
11/2/2023Q3 2023$9.39$10.17+$0.78$11.45$3.23 billion$3.36 billion    
8/3/2023Q2 2023$8.48$10.24+$1.76$9.08$3.02 billion$3.16 billion    
5/4/2023Q1 2023$7.71$8.44+$0.73$9.71$2.92 billion$3.16 billion
2/3/2023Q4 2022$8.18$12.56+$4.38$11.42$3.11 billion$3.41 billion    
11/3/2022Q3 2022$8.55$9.98+$1.43$8.30$2.79 billion$2.94 billion
8/3/2022Q2 2022$8.53$9.77+$1.24$12.07$2.80 billion$2.86 billion    
5/4/2022Q1 2022$9.37$11.49+$2.12$14.37$2.69 billion$2.97 billion    
2/4/2022Q4 2021$18.49$23.72+$5.23$27.75$4.49 billion$4.95 billion    
11/4/2021Q3 2021$9.81$15.37+$5.56$16.41$2.80 billion$3.45 billion    
8/5/2021Q2 2021$8.81$25.80+$16.99$27.97$3.90 billion$5.14 billion    
5/6/2021Q1 2021$7.78$9.89+$2.11$10.09$2.69 billion$2.53 billion  

Regeneron Pharmaceuticals Earnings - Frequently Asked Questions

When is Regeneron Pharmaceuticals's earnings date?

Regeneron Pharmaceuticals has confirmed that its next quarterly earnings data will be published on Thursday, May 2nd, 2024. Learn more on REGN's earnings history.

Did Regeneron Pharmaceuticals beat their earnings estimates last quarter?

In the previous quarter, Regeneron Pharmaceuticals (NASDAQ:REGN) reported $11.86 earnings per share (EPS) to beat the analysts' consensus estimate of $10.73 by $1.13. Learn more on analysts' earnings estimate vs. REGN's actual earnings.

How can I listen to Regeneron Pharmaceuticals's earnings conference call?

The conference call for Regeneron Pharmaceuticals's latest earnings report can be listened to online. Listen to Conference Call

How can I read Regeneron Pharmaceuticals's conference call transcript?

The conference call transcript for Regeneron Pharmaceuticals's latest earnings report can be read online. Read Transcript

How much revenue does Regeneron Pharmaceuticals generate each year?

Regeneron Pharmaceuticals (NASDAQ:REGN) has a recorded annual revenue of $13.12 billion.

How much profit does Regeneron Pharmaceuticals generate each year?

Regeneron Pharmaceuticals (NASDAQ:REGN) has a recorded net income of $3.95 billion. REGN has generated $34.75 earnings per share over the last four quarters.

What is Regeneron Pharmaceuticals's price-to-earnings ratio?

Regeneron Pharmaceuticals (NASDAQ:REGN) has a trailing price-to-earnings ratio of 25.81 and a forward price-to-earnings ratio of 23.24. The price/earnings-to-growth ratio is 2.58.

What is Regeneron Pharmaceuticals's EPS forecast for next year?

Regeneron Pharmaceuticals's earnings are expected to grow from $38.59 per share to $40.13 per share in the next year, which is a 3.99% increase.


More Earnings Resources from MarketBeat

This page (NASDAQ:REGN) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners